On Monday, Eli Lilly And Co (NYSE:LLY) announced data from a VIVID-1 Phase 3 study that evaluated the safety and efficacy of ...

Eli Lilly and Company (NYSE: LLY) announced data demonstrating more patients with moderately to severely active Crohn's ...

US pharma major Eli Lilly has released new data demonstrating more patients with moderately to severely active Crohn's ...

(RTTNews) - Eli Lilly and Company (LLY) Monday announced 1-year histologic data from the Phase 3 VIVID-1 study of mirikizumab in people with Crohn's disease, a type of inflammatory bowel disease.

Lilly announces positive results from phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease: Indianapolis Tuesday, October 15, 2024, 18:00 Hrs [IST] Eli Lilly a ...

Data show more patients treated with mirikizumab achieved histologic response at Week 52 compared to ustekinumab New data are first-of-its-kind analysis of microscopic mucosal resolution that go beyon ...

Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Monday after the U.S. Food and Drug Administration said it would ...

Results from the national "Urgent Conversations" survey, announced today by Eli Lilly and Company , found that over half (60%) of the general population struggle to find a public restroom, a challenge ...

Shares of drug maker Eli Lilly ($LLY) were little changed at the time of writing despite announcing results from its Phase 3 ...

Eli Lilly has the results it was looking for in a second, confirmatory trial of its anti-IL-23p19 antibody mirikizumab in ulcerative colitis as it waits for the outcome of regulatory reviews in ...

Arch Capital Group Ltd. today announced that Nicolas Papadopoulo has been named Chief Executive Officer and is joining the Board of Directors effective immediately. Papadopoulo has held his current ...

Just this week Eli Lilly reported that its IL-23 inhibitor mirikizumab outperformed Cosentyx in the OASIS trial, setting up regulatory filings later this year. Meanwhile, AbbVie’s already ...